The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholder.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx Pharmaceuticals’ Earnings Call: Progress Amidst Funding Challenges
- Acurx assumed with a Buy at H.C. Wainwright
- Acurx Pharmaceuticals: Promising Antibiotic Developments and Strong Financial Position Justify Buy Rating
- Acurx Pharmaceuticals Reports Improved Q1 2025 Results
- Acurx Pharmaceuticals Enters $12M Stock Purchase Agreement